Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU
Company Details
- Employees
- 36
- Founded
- -
- Address
- 37 Bligh St, Suite 1006,level 10,australia
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- imugene.com
- Keywords
- Immuno-oncology, Cancer Vaccines, Her-2+ cancers, Mimotopes, PD-1, biotechnology, immunotherapy, biotech, immune system, cancer experts, B-cell peptide vaccines, b-cell, B-cell vaccine technology, cancer therapy, drug development, immune checkpoint inhibitor monoclonal antibodies.
- HQ
- Sydney, New South Wales
Imugene Limited Questions
Imugene Limited's website is imugene.com
Imugene Limited's LinkedIn profile is https://au.linkedin.com/company/imugene
Imugene Limited has
36 employees.
View email and phone details for 36
employees at Imugene Limited.
Imugene Limited's industry is
Biotechnology Research
Imugene Limited's top competitors are
Kincell Bio,
Precision Biosciences, Inc.,
Immunomic Therapeutics, Inc.,
Prescient Therapeutics,
Mesoblast Limited,
Cartherics Pty Ltd,
Vacv Biotherapeutics,
Carina Biotech,
Cynata Therapeutics,
Chimeric Therapeutics.
Imugene Limited's categories are Biotechnology Research
Imugene Limited's founding year is 2013
